References
Fulton B, Sorkin EM. Propofol: an overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 1995; 50(4): 636–57
Critical care: sedation and inotropic support. Drug Ther Perspect 1993 Aug 2; 2(2): 9, 11–12
British National Formulary No. 30. London: The Pharmaceutical Press, 1995
1995 Physicians GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1995
Nollet G, Verbeke J. Comparison of propofol and alfentanil as sedative agents after coronary artery by-pass graft. J Drug Dev 1991 Oct; 4 Suppl. 3: 62–4
Millane TA, Bennett ED, Grounds RM. Isoflurane and propofol for long-term sedation in the intensive care unit. A crossover study. Anaesthesia 1992 Sep; 47: 768–74
UK Committee on Safety of Medicines. Serious adverse effects and fatalities in children associated with the use of propofol (diprivan) for sedation. Current Problems 1992 no. 34
Smith I, White PF, Nathanson M, et al. Propofol: an update on its clinical use. Anesthesiology 1994 Oct; 81(4): 1005–43
Carrasco G, Molina R, Costa J, et al. Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients: a cost-benefit analysis. Chest 1993 Feb; 103: 557–64
Mirenda J, Broyles G. Propofol as used for sedation in ICU. Chest 1995 Aug; 108: 539-48
Rights and permissions
About this article
Cite this article
Propofol: fast onset and short duration of action offers advantages in short-term ICU sedation. Drugs Ther. Perspect 7, 1–5 (1996). https://doi.org/10.2165/00042310-199607030-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199607030-00001